secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001790340-25-000102
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports Q2 net loss $14.4M; highlights 94% OS at 6 months in pancreatic cancer trial
--------------------------------------------------------------------------------

- Net loss of $14.4M ($0.40/share) vs $14.1M ($0.47/share) in Q2 2024; cash $26.4M as of June 30.
- 94% overall survival at 6 months in Phase 2a of atebimetinib + mGnP in first-line pancreatic cancer (n=34); median OS not reached.
- Third-line pancreatic cancer patient on atebimetinib monotherapy >18 months with confirmed partial response and 34% tumor reduction.
- US composition of matter patent granted for atebimetinib provides exclusivity into 2042; pivotal trial expected in 2026.
- Cash runway sufficient into 2026; End of Phase 2 meeting request submitted to FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000102/0001790340-25-000102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000102/imrx-20250813.htm
  HTML page:      https://secwatch.observer/filing/0001790340-25-000102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer